1. Market Research
  2. > Pharmaceutical
  3. > Drug Delivery Market Trends
  4. > US Drug Delivery Product Market

US Drug Delivery Product Market

  • December 2015
  • -
  • Freedonia
  • -
  • 373 pages

US demand to reach $251 billion in 2019
US demand for drug delivery products is forecast to grow 6.1 percent annually to $251 billion in 2019. Specialized dosage formulations that improve therapies for autoimmune, cancer, cardiovascular, neurological, viral, and other debilitating disorders will lead gains. Included in this group are human and humanized monoclonal antibodies, polymer-encapsulated medicines, and brachytherapy seeds. Among drug delivery devices, pen injectors and retractable prefillable syringes will record the fastest revenue growth based on safety, infection prevention, and ease-of-use advantages. Demand for oral drug delivery products will benefit from bioavailability and reduced dosing advantages, while controlled-release formulations will continue to dominate revenues. On the downside, patent expirations and generic competition will soften overall growth potential for this product segment.

Prefillable syringes to lead strong gains in parenteral drug delivery

US demand for parenteral drug delivery products is projected to post double-digit gains through 2019. Advances in monoclonal antibodies and polymer-encapsulated medicines will underlie growth. The use of new and existing therapies based on human and humanized monoclonal antibodies will improve the effectiveness of remedies against various forms of cancer and other long-term disorders, such as allergy-linked asthma, Crohn’s disease, rheumatoid and psoriatic arthritis, and wet age-related macular degeneration. Enhanced bioavailability and reduced toxicity advantages will boost applications for polymer-enhanced medicines in the treatment of conditions such as cancer complications, hepatitis B and C, and multiple sclerosis.
Among parenteral delivery devices, prefillable syringes will account for the largest and fastest expanding demand over the long term. Improvements in safety features such as automatic needle retraction, along with overall infection prevention and response time advantages, will benefit growth. Prefillable syringes will also broaden self-use applications based on advances in pen injectors and related apparatus.

Table Of Contents

US Drug Delivery Product Market
INTRODUCTION x
I. EXECUTIVE SUMMARY 1
II. MARKET ENVIRONMENT 4
General 4
Economic Factors 5
Demographic Patterns 9
Healthcare Trends 12
Health Insurance Reforms 13
Medical Conditions 16
Acute Conditions 16
Chronic Conditions 17
National Health Expenditures 20
Spending Categories 21
Funding Sources 24
Medical Providers 27
Hospitals 28
Outpatient Facilities 29
Physicians 30
Skilled Nursing Homes 30
Patient Activity 31
Hospital Activity 32
Outpatient Activity 33
Surgical Procedures 33
Pharmaceutical Industry Overview 34
Regulation 35
Research and Development 38
Product Demand 38
Therapeutic Groups 39
Dosage Formulations 41
Regulatory Classes 43
Commercial Status 45
III. DRUG DELIVERY PRODUCT OVERVIEW 49
General 49
Types of Drug Delivery Products 50
Historical Market Trends 53
US Trade 55
International Markets 57
IV. ORAL DRUG DELIVERY PRODUCTS 59
General 59
Controlled-Release Formulations 61
Film-Coated Formulations 65
Diffusion Formulations 68
Reservoir Formulations 70
Chewable Tablets 72
Orally Disintegrating Tablets 74
Nanoparticulate Formulations 77
Transmucosal Formulations 81
V. PARENTERAL DRUG DELIVERY PRODUCTS 85
General 85
Therapeutic Monoclonal Antibodies 87
Technology 89
Products 91
HUMIRA (adalimumab) 91
REMICADE (infliximab) 92
RITUXAN (rituximab) 92
AVASTIN (bevacizumab) 92
HERCEPTIN (trastuzumab) 93
LUCENTIS (ranibizumab) 93
STELARA (ustekinumab) 94
XOLAIR (omalizumab) 94
TYSABRI (natalizumab) 95
Other Monoclonal Antibodies 95
New Products 99
Developmental Products 103
Encapsulated Parenteral Formulations 104
Polymer-Protected Formulations 105
PEG-Based Parenteral Therapies 106
Other Polymer-Protected Parenteral Therapies 110
Developmental Activities 111
Liposomes 112
Technology 113
Marketed Products 113
Developmental Activities 116
Infusion Products 117
IV Administration Sets 118
Premixed IV Solutions 120
Infusion Pumps 121
Other Infusion Products 123
Enteral Feeding Supplies 124
IV Accessories 124
Parenteral Devices 125
Prefillable Syringes 126
Injectors 127
Cartridge Systems 129
Hypodermic Syringes 132
IV Catheters 134
Other Parenteral Devices 135
VI. OTHER DRUG DELIVERY PRODUCTS 137
General 137
Inhalation Drug Delivery Products 138
Dry Powder Formulations 139
Metered Dose Formulations 142
Transdermal Drug Delivery Products 145
Transdermal Technologies 146
Central Nervous System Agents 148
Hormones and Related Agents 151
Cardiovascular Agents 154
Other Transdermal Patches 154
Implantable Drug Delivery Products 155
Drug Inserts 156
Drug-Eluting Stents 159
Other Implantable Drug Delivery Products 162
Brachytherapy Products 163
Implantable Drug Pumps 165
VII. APPLICATIONS 168
General 168
Central Nervous System Agents 170
Controlled-Release Formulations 171
Other Oral Drug Delivery Products 173
Transdermal Formulations 174
Monoclonal Antibodies and Polymer Encapsulated Therapies 176
Liposomes 178
Other Drug Delivery Products 178
Hormones and Related Agents 179
Anticancer Monoclonal Antibodies 180
Encapsulated Polymers 185
Liposomes 186
Insulin Pen Injectors 188
Controlled-Release and Other Oral Drug Delivery Products 190
Transdermal Hormones and Related Agents 191
Other Drug Delivery Products 192
Respiratory Agents 194
Dry Powder Inhalers 195
Metered Dose Inhalers 197
Monoclonal Antibodies 199
Anti-Infective Agents 200
Cardiovascular Agents 202
Controlled-Release Formulations 203
Monoclonal Antibodies 204
Drug-Eluting Stents 205
Transdermal Patches 207
Gastrointestinal Agents 207
Nutritional Agents 210
Other Pharmaceuticals 212
VIII. INDUSTRY STRUCTURE 217
General 217
Market Share 219
Dosage Formulations 219
Devices 220
Competitive Strategies 222
Mergers and Acquisitions 224
Licensing and Related Agreements 227
Marketing and Distribution 233
Manufacturing 234
Company Profiles 235
Abbott Laboratories 236
AbbVie Incorporated 239
Actavis, see Allergan
Adare Pharmaceuticals Incorporated 242
Allergan plc 246
Amgen Incorporated 251
Animas, see Johnson and Johnson
Aptalis Pharma, see Allergan
Aptalis Pharmaceutical Technologies, see Adare
Pharmaceuticals
AptarGroup Incorporated 255
AstraZeneca plc 258
Baxter International Incorporated 263
Becton, Dickinson, and Company 266
Boehringer Ingelheim GmbH 274
Braun (B.) Melsungen AG 278
Bristol-Myers Squibb Company 281
CareFusion, see Becton, Dickinson
Evonik Industries AG 285
Forest Laboratories, see Allergan
Genentech, see Roche Holding
Genzyme, see Sanofi
Gerresheimer AG 288
Gilead Sciences Incorporated 292
GlaxoSmithKline plc 295
Hospira, see Pfizer
ImClone Systems, see Lilly (Eli)
Janssen Pharmaceuticals, see Johnson and Johnson
Johnson and Johnson 300
Lilly (Eli) and Company 306
MedImmune, see AstraZeneca
Merck and Company Incorporated 311
Nitto Denko Corporation 316
Novartis AG 319
Novo Nordisk A/S 326
Pfizer Incorporated 330
Regeneron Pharmaceuticals, see Sanofi
Roche Holding Limited 339
Sanofi 344
Teva Pharmaceutical Industries Limited 350
3M Company 355
Unilife Corporation 359
Vetter Pharma International GmbH 364
West Pharmaceutical Services Incorporated 366
Additional Companies in the Drug Delivery Product Market 370
Summary Table 3
SECTION II -- MARKET ENVIRONMENT
1 Macroeconomic Indicators 9
2 Resident Population by Age Group 12
3 Health Insurance Coverage of the US Population, 2004-2014 15
4 Acute Conditions by Type 17
5 Chronic Conditions by Type 20
6 National Health Expenditures by Spending Category 24
7 National Health Expenditures by Funding Source 27
8 Medical Providers by Type 28
9 Patient Activity by Type 32
10 Pharmaceutical Demand by Therapeutic Class 41
11 Pharmaceutical Demand by Dosage Formulation 43
12 Pharmaceutical Demand by Regulatory Classification 45
13 Pharmaceutical Demand by Patent Status 48
SECTION III -- DRUG DELIVERY PRODUCT OVERVIEW
1 Drug Delivery Product Demand by Type 50
2 Drug Delivery Product Demand Patterns, 2004-2014 55
3 US Trade in Drug Delivery Products 56
4 World Drug Delivery Product Demand by Region 58
SECTION IV -- ORAL DRUG DELIVERY PRODUCTS
1 Oral Drug Delivery Product Demand by Type 61
2 Controlled-Release Oral Drug Delivery Product Demand 64
3 Film-Coated Oral Drug Delivery Product Demand 68
4 Diffusion Oral Drug Delivery Product Demand 70
5 Reservoir Oral Drug Delivery Product Demand 72
6 Chewable Tablet Product Demand by Therapeutic Class 74
7 Orally Disintegrating Tablet Demand by Therapeutic Class 77
8 Oral Nanoparticulate Drug Delivery Product Demand by
Therapeutic Class 81
9 Transmucosal Drug Delivery Product Demand by
Therapeutic Class 84
SECTION V -- PARENTERAL DRUG DELIVERY PRODUCTS
1 Parenteral Drug Delivery Product Demand by Type 86
2 Therapeutic Monoclonal Antibody Demand by Therapeutic
Class 88
3 Encapsulated Parenteral Product Demand by Type
and Therapeutic Class 105
4 Infusion Product Demand by Type 118
5 Parenteral Device Demand by Type 126
SECTION VI -- OTHER DRUG DELIVERY PRODUCTS
1 Other Drug Delivery Product Demand by Type 138
2 Inhalation Drug Delivery Product Demand by Type 139
3 Dry Powder Inhaler Demand 142
4 Metered Dose Inhaler Demand 145
5 Transdermal Drug Delivery Product Demand by
Therapeutic Class 146
6 Implantable Drug Delivery Product Demand by Type 156
7 Drug Insert Demand by Therapeutic Class 159
8 Drug-Eluting Stent Demand 162
9 Other Implantable Drug Delivery Product Demand by Type 163
SECTION VII -- APPLICATIONS
1 Drug Delivery Product Demand by Therapeutic Class 169
2 Central Nervous System Drug Delivery Product Demand
by Type 171
3 Hormone and Related Drug Delivery Product Demand by Type 180
4 Respiratory Drug Delivery Product Demand by Type 195
5 Anti-Infective Drug Delivery Product Demand by Type 201
6 Cardiovascular Drug Delivery Product Demand by Type 203
7 Gastrointestinal Drug Delivery Product Demand by Type 210
8 Nutritional Preparation Delivery Product Demand by Type 212
9 Other Application Drug Delivery Product Demand by Type 216
SECTION VIII -- INDUSTRY STRUCTURE
1 US Drug Delivery Product Sales by Company, 2014 218
2 Selected Acquisitions and Divestitures 225
3 Selected Cooperative Agreements 228

LIST OF CHARTS

SECTION III -- DRUG DELIVERY PRODUCT OVERVIEW
1 Drug Delivery Product Demand by Type, 2014 52
SECTION V -- PARENTERAL DRUG DELIVERY PRODUCTS
1 Parenteral Drug Delivery Product Demand by Type, 2014 87
SECTION VII -- APPLICATIONS
1 Drug Delivery Product Demand by Therapeutic Class, 2014 170
SECTION VIII -- INDUSTRY STRUCTURE
1 Drug Delivery Formulations, US Market Share, 2014 220
2 Drug Delivery Devices, US Market Share, 2014 222

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
North American Drug Delivery Technologies Market by Route of Administration, Pulmonary, Injectable, Ocular, Nasal, Topical, Implantable), End User - Global Forecast to 2021

North American Drug Delivery Technologies Market by Route of Administration, Pulmonary, Injectable, Ocular, Nasal, Topical, Implantable), End User - Global Forecast to 2021

  • $ 5650
  • Industry report
  • August 2016
  • by MarketsandMarkets

The North American drug delivery technologies market is projected to reach USD 758.7 billion by 2021 from USD 520.0 billion in 2016, at a CAGR of 6.5% during the forecast period. Major factors contributing ...

European Market Overview for Diabetes Monitoring, Treatment and Drug Delivery 2016 - MedView

European Market Overview for Diabetes Monitoring, Treatment and Drug Delivery 2016 - MedView

  • $ 4995
  • Industry report
  • September 2016
  • by iData Research, Inc.

The European diabetes diagnosis, treatment and drug delivery market increased in 2015 and growth is expected to persist over the forecast period. Market growth will be driven by the growing prevalence ...

Injectable Drug Delivery Market Analysis, By Device Type, By Formulation, By Therapeutic Use, By End-user Application, By Region And Segment Forecasts From 2013 to 2024

Injectable Drug Delivery Market Analysis, By Device Type, By Formulation, By Therapeutic Use, By End-user Application, By Region And Segment Forecasts From 2013 to 2024

  • $ 4950
  • Industry report
  • August 2016
  • by Grand View Research

The global injectable drug delivery market is expected to reach USD 931.1 billion by 2024, according to a new report by Grand View Research, Inc. The increase in number of chronic diseases like diabetes ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.